‘No more sponsored lavish dinners, cocktail parties for doctors’: NMC lays down new guidelines

Medical conferences held at luxurious hotels with lavish dinners and cultural festivities might soon become a thing of the past due to new rules from the National Medical Commission.

These regulations prohibit doctors from participating in any seminars, workshops, or conferences that receive sponsorships, either directly or indirectly, from pharmaceutical companies or the allied health sector.

Breaching these regulations could result in the suspension of a doctor’s license for a period of three months.

Section 35 of these fresh professional conduct guidelines also prevents doctors and their families from receiving consultancy fees or honorariums from pharmaceutical companies or their representatives.

Related Posts

Unnecessary use of steroid leads to risk of severe fungal infections: Doctors

Pune:  After the use of steroids for routine viral fevers and mild respiratory infections has grown among people, doctors in the city warned that it could increase the risk of…

Spurious cosmetic packaging factory busted in northwest Delhi

New Delhi: In a significant breakthrough under ‘Operation Kavach,’ the Cyber Cell of the Crime Branch, Delhi, has unearthed a major illegal manufacturing unit involved in the fabrication of empty…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Unnecessary use of steroid leads to risk of severe fungal infections: Doctors

Unnecessary use of steroid leads to risk of severe fungal infections: Doctors

Spurious cosmetic packaging factory busted in northwest Delhi

Spurious cosmetic packaging factory busted in northwest Delhi

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

UP plans US FDA-accredited medical device testing lab

UP plans US FDA-accredited medical device testing lab

Patent rejected for MNC’s cancer drug, generics to follow

Patent rejected for MNC’s cancer drug, generics to follow

Zydus brings world’s first Nivolumab biosimilar to India

Zydus brings world’s first Nivolumab biosimilar to India